FAP and colorectal carcinoma: The first clinical experience of FAP-targeted scintigraphic imaging was reported by Welt et al. in 1994, using the 131I-labeled murine monoclonal antibody (mAb) F19 in patients with metastatic colorectal cancer (CRC) [18].